Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Global Computational Biology Sector Expected to Reach over USD 4 Billion by 2020

By LabMedica International staff writers
Posted on 17 Aug 2014
The global market for computational biology is expected to reach USD 4.285 billion by 2020 growing at a compound annual growth rate (CAGR) of 21.1%, according to new market research.

Steady surge in the usage and application of computational biology for bioinformatics R&D programs designed for sequencing genomes to better determine biologic systems and increasing number of clinical studies in pharmacogenomics and pharmacokinetics for novel drug discovery studies are expected to drive computational biology demand over the next six years, according to a recent market report published by Grand View Research, Inc. More...
(San Francisco, CA,USA), a market research and consulting company.

Computational genomics for cellular and biologic simulation applications lead the market in 2013, accounting for over 47% of global revenue. Major factors fueling demand for these applications include the growth of drug designing, disease modeling and personalized medicine applications and the growing usage of computational biology for functional and structural genomics, epigenomics and metagenomics for the analysis of protein transcription, protein-protein interactions, gene sequencing and expression and three-dimensional (3D) protein structure analysis.

Further key findings from the study suggest that North America was the largest regional market, accounting for 58.0% of the global revenue in 2013. Its large share is mostly credited to the growing research investments and initiatives for development of drug discovery, disease modeling technologies and advances in biologic computation technology. It is expected that Asia Pacific will see the most rapid growth in the market, at an estimated CAGR of 28.0% due to the increasing expenditure in clinical studies for pharmacokinetics and pharmacogenomics.

Another finding included that the application of computational biology in proteomics for cellular simulation is expected to grow at the fastest CAGR of over 22%, due to the swing in sequencing studies towards additional analysis of the nature of various biologic proteins as a part of development of personalized medicine.

Drug discovery and disease modelling applications were found to dominate the market, accounting for 58.0% of global revenue in 2013. This large share is attributed by the extensive drug development pipelines present for a number of global branded and generic drug manufacturing firms such as Sanofi, Novo Nordisk, and Eli Lilly.

Computational Biology databases dominated the tools segment and accounted for 44.5% of the market revenue in 2013, owing to extensive genomic database usage for warehousing and data mining of biologic and sequential data generated from genomic and proteomic studies. Consequentially, the software and services for the analysis of biologic data is expected to witness the fastest CAGR of over 21.0%. Major companies in this market include Schrodinger, Accelrys, Certara, Entelos, Simulation Plus, and others.

Grand View Research provides customized research reports and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials, and energy.

Related Links:

Grand View Research



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.